HealthLynked (OTCQB: HLYK) has announced its Q3 2024 financial results, reflecting a strategic shift toward software solutions and a leaner operational model. Revenue dropped 56% year-over-year to $0.59 million, attributed to disruptions from clinical restructuring efforts, while operating expenses fell 10% in Q3 and 19% year-to-date due to efficiency initiatives. However, the company reported a $1.97 million net loss for the quarter, primarily due to the absence of a one-time $1.08 million gain recorded in 2023. HealthLynked is pivoting away from traditional clinical operations, focusing on app-based services to expand its user base and enhance operational scalability.
To view the full press release, visit https://ibn.fm/dDwF5
About HealthLynked Corp.
HealthLynked Corp. is committed to improving global healthcare by facilitating the efficient exchange of medical information between patients and providers. The company’s network empowers members to actively manage their healthcare through a centralized and secure platform. For more information about HealthLynked Corp., please visit www.healthlynked.com.
NOTE TO INVESTORS: The latest news and updates relating to HealthLynked are available in the company’s newsroom at https://IBN.fm/HLYK
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed the company’s efforts…
Earth Science Tech (OTCQB: ETST) is leveraging artificial intelligence (“AI”), proprietary software and its in-house…
This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid…
This article has been disseminated on behalf of Adaptogenics Health Corp. and may include paid…
Oncotelic Therapeutics (OTCQB: OTLC) announced the publication of a peer-reviewed study in Biomedicines demonstrating how…
VERAXA Biotech (NASDAQ: VRXA) is developing antibody-based cancer therapies designed to improve treatment selectivity and…